| Autor: |
Grandi, Giovanni, Del Savio, Maria Chiara, Lopes da Silva-Filho, Agnaldo, Facchinetti, Fabio |
| Předmět: |
|
| Zdroj: |
Expert Review of Clinical Pharmacology; Apr2020, Vol. 13 Issue 4, p327-330, 4p |
| Abstrakt: |
Keywords: Hormonal contraception; combined hormonal contraceptives; ethinyl-estradiol; estradiol; estetrol; drospirenone; levonorgestrel; hemostasis; metabolism; venous thromboembolic events; cardiovascular risks EN Hormonal contraception combined hormonal contraceptives ethinyl-estradiol estradiol estetrol drospirenone levonorgestrel hemostasis metabolism venous thromboembolic events cardiovascular risks 327 330 4 07/14/20 20200401 NES 200401 1. Compared with EE/DRSP, combinations E4/DRSP and E4/LNG were associated with a lower effect on sex hormone-binding globulin (SBHG) (-69% to - 44% in E4/LNG, +8% to +44% in E4/DRSP and +306% in EE/DRSP, respectively). Because E4/DRSP exerted considerably lower hepatic and vascular estrogenicity than EE/DRSP, the authors suggested that women who take E4-containing COCs may ultimately prove to have a lower risk of venous thromboembolism compared to women who take EE-containing COCs. Subjects with an intact uterus were randomized to receive 2 mg E4 or E2 V for 28 days with subsequent dose-escalation groups (non-randomized) to 10 mg E4 (intact uterus and >= 35 hot flushes per week) and 20 and 40 mg E4 (hysterectomized subjects). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
